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pathogen due to its ability for survival in the hospital environment on a wide range of dry and moist surfaces.[4,6]Earlier, it is believed to be non-pathogenic, but recently, they are very frequently isolated as primary pathogen. Usually, they cause hospital-acquired infection (HAI).[7] They are most commonly involved the respiratory tract, where endotracheal tubes are 
in situ or patients have undergone tracheostomy. Apart from this, the other infections caused by Acinetobacter are urinary tract infection (UTI), where catheter in situ or from wounds or surgical sites where drain tips are inserted, endocarditis, meningitis, peritonitis in patients receiving peritoneal dialysis, and bacteremia.[2,6,7]The isolation rate of Acinetobacter has been increasing nowadays in tertiary care hospital. Unfortunately, a very few laboratories can 
INTRODUCTION
Acinetobacter species are non-fermenting Gram-negative bacilli (NFGNB).[1] They are non-spore forming coccobacilli that either do not utilize carbohydrates as the source of energy or degrade them through metabolic pathway.[2] They are widely distributed in nature as saprophytes, found in soil, sewage, water, or on human skin and gut and also in hospital environment.[1,3,4] These bacteria remain stable under an extreme conditions of temperature, humidity, and pH and in the presence of commonly used detergents such as highly concentrated alcohol preparations and other antiseptics which normally inhibit the growth of other bacteria.[5] This stability offers Acinetobacter a growth advantage over other organisms in hospital environments. Hence, in the recent era, they have emerged as an important nosocomial 
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Background: Acinetobacter is widely distributed in nature as saprophytes. Recently, they have emerged as a nosocomial pathogen 
due to its ability for survival in the hospital environment on a wide range of dry and moist surface. They cause pneumonia, urinary 
tract infection (UTI), and surgical site infection (SSI) where drain tips are inserted, endocarditis, meningitis, peritonitis, and 
bacteremia. Antibiotic susceptibility pattern of Acinetobacter may vary geographically. Due to multidrug resistance patterns of 
Acinetobacter, it is imperative to know the institutional prevalent susceptibility profiles. 
Aims and Objectives: This study was conducted to isolate Acinetobacter species from various clinical samples, to determine the 
antibiotic susceptibility pattern and to carry out the epidemiological investigation of the isolates. 
Materials and Methods: The study was conducted in a tertiary care hospital, over a period of 2 years. After identification, the 
speciations of Acinetobacter isolates were done by biochemical tests and by VITEK 2. Antibiotic susceptibility was determined by 
disc diffusion method. Extended-spectrum β-lactamases (ESBLs) and metallo-β-lactamases (MBLs) production were detected 
by the combined disc diffusion test. An epidemiological study of Acinetobacter was carried out. 
Results: Of 5096 infected samples, 505 (9.9%) were non-fermenting Gram-negative bacilli, among which 170 (33.8%) were 
found to be Acinetobacter. The highest numbers of isolates were Acinetobacter baumannii, followed by Acinetobacter lwoffii, 
Acinetobacter radioresistance, Acinetobacter calcoaceticus, Acinetobacter Haemolyticus, and Acinetobacter ursingii. Highest 
incidences of susceptibility were to imipenem (60%), chloramphenicol, and gentamicin. ESBL and MBL productions were detected 
in 23% and 17%, respectively. 
Conclusion: A high level of antibiotic resistance was observed in this study and maximum isolation rate was in SSI. Most of 
the patients had high-risk factors such as prolonged hospitalization, indwelling catheters, and orthopedics implants in situ or 
other catheterization and diabetes. The analysis of susceptibility pattern will be useful in understanding the epidemiology of this 
organism in our hospital setup.
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isolate and identify them up to species level. Moreover, they pose a great threat to humankind as they are resistance to common antibiotics.[2] The antibiotic susceptibility pattern of Acinetobacter may vary widely geographically. However, due to unpredictable multidrug resistance (MDR) patterns of clinical strains of 
Acinetobacter, it is imperative to know the institutional prevalent susceptibility profiles. Hence, this study was conducted to isolate the Acinetobacter species from various clinical samples by a simplified phenotypic identification protocol and to determine the antibiotic susceptibility pattern of these isolates.[8]
MATERIALS AND METHODSThis was a prospective study. The study was conducted in the Microbiology Department of Dr. D.Y. Patil Medical College, Hospital and Research Centre, over a period of 2 years (i.e., July 2012–September 2014). A total of 15,169 clinical samples of pus, blood, body fluid (pleural fluid, peritoneal fluid, synovial fluid, etc.), urine, sputum, cerebral spinal fluid, and throat swab were carried out. The blood samples from the suspected patients of sepsis were collected in the adult and pediatric bottles of BACT/ALERT three-dimensional system. The samples were taken from the suspected patients, admitted to different wards and various intensive care units (ICU) of this hospital. A detailed history was taken. The study was approved by the Ethical Committee of our institute (Dr. D.Y. Patil Medical College and Research Centre). The statistical analysis was performed with the help of Microsoft EXCEL for WINDOWS 2007.Samples were processed for culture by standard conventional methods. Genus Acinetobacter was identified by Gram staining (Gram-negative coccobacilli), cell and colony morphology [Figure 1], positive catalase test, positive citrate test, triple sugar iron (alkaline slant/no change butt), negative oxidase test, and absence of motility. Speciation of Acinetobacter was performed on the basis of Hugh and Leifson oxidative-fermentative test (O-F) for glucose, sucrose, lactose, mannitol, gelatin liquefaction, beta hemolysis on blood agar media, nitrate reduction test, urease hydrolysis test (Christensen), decarboxylation of arginine, lysine, and ornithine and growth at 35°C and at 42°C for 18–24 h on two tubes of trypticase soy agar). The final identification and confirmation were done by the Vitek 2 system.[2,9]Antibiotic susceptibility testing was determined by Kirby–Bauer disc diffusion method[2,10] Mueller-Hinton agar media was used. Commercially available HiMedia discs were used. The strength of the discs used and their zone size interpretation was carried out by National Committee for Clinical Laboratory Studies Guideline. The antibiotics, which were tested, ampicillin (10 mcg/disc), cefotaxime (30 mcg/disc), ceftazidime (CAZ) (30 mcg/disc), gentamicin (10 mcg/disc), amikacin (30 mcg/disc), norfloxacin (10 mcg/disc), cotrimoxazole (25 mcg/disc), imipenem (10 mcg/disc), chloramphenicol (30 mcg/disc), ofloxacin (5 mcg/disc), amoxicillin/clavulanic acid (20/10 mcg/disc), piperacillin/tazobactam (100/10 mcg/disc), tigecycline (15 mcg/disc), colistin (10 mcg/disc), and ertapenem (10 mcg/disc). Acinetobacter isolated from urine samples were also tested with nitrofurantoin (300 mcg), nalidixic acid (30 mcg), ampicillin (10 mcg/disc), norfloxacin (10 mcg), cefotaxime (30 mcg), gentamicin (10 mcg), cotrimoxazole (25 mcg), imipenem (10 mcg), amikacin (30 mcg/disc), and CAZ (30 mcg/disc).[10]
Detection of MDR StrainThe isolates which were resistance to three or more than three groups of drugs were considered as MDR strain.[11] The groups of drugs we were tested are: Penicillin (ampicillin), cephalosporin (cefotaxime, CAZ), aminoglycosides (gentamicin, amikacin), cotrimoxazole, carbapenem (imipenem, ertapenem), fluoroquinolones (norfloxacin, ofloxacin, nalidixic acid), nitrofurantoin chloramphenicol, glycylcyclines (tigecycline), and colistin.
Detection of Extended-spectrum β-lactamases 
(ESBLs) Production[10,12]The combine disk diffusion test (CDDT) was used to determine the prevalence of ESBL production. Mueller-Hinton agar media was used. One CAZ (30 µg) disc was placed on a lawn culture of test isolates and at the distance of 15 mm on both sides of CAZ disc, a combination disc of CAZ/tazobactam (30/10 µg) 
and CAZ/clavulanic acid (30/10 µg) were placed. A ≥5 mm increased in a zone diameter for either antimicrobial agent tested in combination with clavulanic acid or tazobactam versus the zone diameter of the agent when tested alone = ESBL producer [Figure 2].[10,12]
Figure 2: Detection of extended-spectrum β-lactamases by combine 
disc diffusion test
Figure 1: Colonies of Acinetobacter radioresistance on blood agar 
media
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Detection of Metallo-β-lactamases (MBLs) 
ProductionMueller-Hinton agar media was used. One imipenem (10 µg) disc was placed on a lawn culture of isolates and at the distance of 15 mm a combination disc of 10 µg of imipenem and 100 µl of EDTA disc was placed. Then, it was incubated at 35°C for 18–24 h. An increase 
in zone size ≥7 mm around the imipenem-EDTA disc as compared to imipenem disc alone was recorded as positive [Figure 3].[10,12]An epidemiological study of Acinetobacter was carried out by means of in-use test [Figure 4]. With a sterile pipette, transferred 1 ml of the used disinfectant into 9 ml of nutrient broth in a sterile universal container and placed 0.02 ml drops of this mixture onto 10 different areas of two well-dried nutrient agar plates. Incubate one plate at 37°C for 3 days and another one at room temperature for 7 days. Read the test as showing failure of disinfection if there was growth in more than five drops in either place.[1,2] To tract the source, 25 samples were isolated from inanimate objects and from disinfectants of different wards and ICUs.[1]
RESULTSIn this study, out of 15,169 clinical samples, a total number of culture-positive isolates were 5096 (33.59 %) among which 1921 (37.69%) were Gram-positive cocci and 3175 (62.3%) were GNB. Of 3175 GNB, 505 (15.9%) were NFGNB. Of the total 505 isolates, 170 (33.66%) were different species of Acinetobacter. 
Acinetobacter species were predominantly isolated from different types of body fluids and from various catheter tips 61 (35.88%) followed by pus 57 (33.53%), blood samples 29 (17.05%), sputum 13 (7.64%), and urine samples 10 (5.88%). Maximum 
Acinetobacter species isolated were from surgical ward (23%) followed by medicine ICU (10.8%) next to it was medicine ward (9.6%). There was a higher incidence of infection among males (69.8%). Acinetobacter infection was more common in patients in the age group of 51–60 years, comprises 16.40% followed by 41–50 years (16%) [Figure 5].The highest number of isolates were Acinetobacter baumannii, comprises 56.47% followed by Acinetobacter lwoffii 20.58%, then 
A. baumannii complex (ABC) 10.58% next to it was Acinetobacter 
radioresistance comprises 4.7%, Acinetobacter calcoaceticus 4.11%, Acinetobacter haemolyticus 2.94%, and Acinetobacter 
ursingii 0.58% [Table 1].Highest number of Acinetobacter species were isolated from surgical site infection (SSI), comprises 35.88%, followed by 21.17% isolates were yield from the patients who were suffering 
from respiratory tract infection and 20.58% isolates were obtained from the patients who have developed septicemia [Table 2]. In this study, we have analyzed the risk factors for colonization and infection with A. baumannii. Major surgeries, trauma, SSI, prolonged hospitalization, mechanical ventilation, indwelling foreign devices (especially orthopedic implants), diabetes mellitus (DM), and debilitating disease such as tuberculosis and previous antimicrobial therapy all have identified as risk factors which are predisposing to acquisition this infection. In this study, 24.56% 
Table 1: Distribution of Acinetobacter in different clinical samples (n=170)
Name of the organism Pus (%) Body fluid (%) Blood (%) Sputum (%) Urine (%) Total n=170 (%)
A. baumannii 36 29 18 7 6 96 (56.47)
A. lwoffii 13 13 4 4 1 35 (20.58)
ABC 4 8 4 1 1 18 (10.58)
A. radioresistance 0 6 1 0 1 8 (4.7)
A. calcoaceticus 3 1 1 1 1 7 (4.11
A. haemolyticus 1 3 1 0 0 5 (2.9)
A. ursingii 0 1 0 0 0 1 (0.58)
Total (%) 57 (33.53) 61 (35.88) 29 (17.05) 13 (7.64) 10 (5.88) 170
A. baumannii: Acinetobacter baumannii, A. lwoffii: Acinetobacter lwoffii, ABC: Acinetobacter baumannii complex, A. radioresistance: Acinetobacter radioresistance, A. calcoaceticus: 
Acinetobacter calcoaceticus, A. haemolyticus: Acinetobacter haemolyticus, A. ursingii: Acinetobacter ursingii
Figure 4: In-Use test
Figure 3: Detection of metallo-β-lactamases by combine disc diffusion 
test
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isolates were obtained from the patients who have admitted in this hospital for a long tenure. Around 21.05% isolates were obtained from the patients, who were on mechanical ventilators, whereas 17.54% isolates were yield from the patients who were suffering from DM. We had been isolated around 11.40% Acinetobacter species from the immunocompromised patients who were on chemotherapy. 18.42% isolates were yield from the patients who had indwelling catheters or orthopedics implants in situ [Table 3].The isolates of A. baumannii obtained from pus, blood, body fluid, and sputum revealed good susceptibility to imipenem (60%), chloramphenicol (52%) next to it was gentamicin (48.9%) and amikacin (47.8%) [Figure 6]. The other species of Acinetobacter 
other than A. baumannii revealed good susceptibility to imipenem (70%), chloramphenicol (62.85%), amikacin (58.57%), and gentamicin 54.28% [Figure 7]. The Acinetobacter species isolated from urine samples revealed 90% sensitivity to imipenem followed by 80% sensitivity to norfloxacin and nitrofurantoin [Figure 8]. Around 94 (55.29%) isolates of Acinetobacter species were MDR strains, among which 35 isolates (37.23%) were ESBL producer and 29 isolates (30.85%) were MBL producer [Table 4].25 samples from inanimate objects and from disinfectant were collected from different wards and ICUs. Of these 25 samples, 9 (36%) were culture positive among which 44.44% were 
A. baumannii [Table 5].
Table 2: Diagnosis wise distribution of the Acinetobacter species (n=170)
Name of the organism SSI RIT Sepsis GIT CA UTI Surface non‑healing ulcers Burn Total
A. baumannii 33 17 22 10 7 3 3 1 96
ABC 5 9 2 0 0 1 1 0 18
A. lwoffii 14 7 7 3 3 0 1 0 35
A. radioresistance 3 0 2 2 1 0 0 0 8
A. calcoaceticus 3 2 0 0 0 2 0 0 7
A. haemolyticus 2 1 2 0 0 0 0 0 5
A. ursingii 1 0 0 0 0 0 0 0 1
Total (%) 61 (35.88) 36 (21.17) 35 (20.58) 15 (8.82) 11 (6.47) 6 (3.52) 5 (2.94) 1 (0.58) 170
SSI: Surgical site infection, RIT: Repeat infection timeframe, UTI: Urinary tract infection, A. baumannii: Acinetobacter baumannii, ABC: Acinetobacter baumannii complex, 
A. lwoffii: Acinetobacter lwoffii, A. radioresistance: Acinetobacter radioresistance, A. calcoaceticus: Acinetobacter calcoaceticus, A. haemolyticus: Acinetobacter haemolyticus, 
A. ursingii: Acinetobacter ursingii
Table 3: Risk factors wise distribution of the organisms (n=114)
Name of the 
organism
Prolonged 
hospitalization
Ventilation DM Chemotherapy 
due to 
malignancy
Orthopedics 
implants
Indwelling 
intravascular 
catheters
TB Total
A. baumannii 18 12 15 10 7 5 8 75
ABC 1 5 0 1 2 2 0 11
A. lwoffii 6 4 4 1 2 1 0 18
A. radioresistance 1 1 0 1 0 0 0 3
A. calcoaceticus 0 0 1 0 1 1 0 3
A. haemolyticus 1 2 0 0 0 0 0 3
A. ursingii 1 0 0 0 0 0 0 1
Total (%) 28 (24.56) 24 (21.05) 20 (17.54) 13 (11.40) 12 (10.52) 09 (7.89) 8 (7.02) 114
A. baumannii: Acinetobacter baumannii, ABC: Acinetobacter baumannii complex, A. lwoffii: Acinetobacter lwoffii, A. radioresistance: Acinetobacter radioresistance, A. calcoaceticus: 
Acinetobacter calcoaceticus, A. haemolyticus: Acinetobacter haemolyticus, A. ursingii: Acinetobacter ursingii, DM: Diabetes mellitus, TB: Tuberculosis
Figure 5: Age distribution of the patients
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Figure 6: Antibiotic susceptibility pattern of Acinetobacter baumannii isolates was from pus, body fluid, blood, and sputum
Figure 8: Antibiotic susceptibility pattern of Acinetobacter species of urinary isolates
A. baumannii isolated from pus, body fluid, blood, and sputum revealed good susceptibility to imipenem (60%), followed by chloramphenicol (52.22%) and gentamicin (48.88%). The isolates of Acinetobacter species, other than A. baumannii revealed a good sensitivity to imipenem (70%) followed by chloramphenicol (62.85%) and amikacin (58.57%).
Figure 7: Antibiotic susceptibility pattern of Acinetobacter species, other than Acinetobacter baumannii isolates were from pus, body fluid, blood, 
and sputum
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Table 4: Distribution of MDR strains of Acinetobacter species
Name of the organisms Total number of isolates Total number of MDR ESBL MBL
A. baumannii 96 55 23 17
ABC 18 8 1 2
A. lwoffii 35 20 7 7
A. radioresistance 8 3 2 1
A. calcoaceticus 7 6 1 2
A. haemolyticus 5 2 1 0
A. ursingii 1 0 0 0
Total (%) 170 94 (55.29) 35 (37.23) 29 (30.85)
MDR: Multidrug resistance, ESBLs: Extended‑spectrum β‑lactamases, MBLs: M etallo‑β‑lactamases, A. baumannii: Acinetobacter baumannii, ABC: Acinetobacter baumannii 
complex, A. lwoffii: Acinetobacter lwoffii, A. radioresistance: Acinetobacter radioresistance, A. calcoaceticus: Acinetobacter calcoaceticus, A. haemolyticus: Acinetobacter 
haemolyticus, A. ursingii: Acinetobacter ursingii
Table 5: Epidemiological study
Inanimate objects 
or disinfectants
Ward Growth
Washbasin MSW P. aeruginosa
Washbasin FSW MRSA
Washbasin MMW A. baumannii
Washbasin FMW MSSA
Air condition machine NICU No Growth
Warmer NICU No growth
Humidifier PICU No growth
Humidifier SICU No growth
Disinfectant MSW A. baumannii
Disinfectant FSW MRSA
Disinfectant MOW A. baumannii
Disinfectant FOW MSSA
Disinfectant OBGY A. baumannii
Disinfectant M. OPTHAL WARD No growth
Disinfectant F. OPTHAL WARD No growth
Disinfectant M. ENT No growth
Disinfectant F. ENT No growth
Disinfectant PICU No growth
Disinfectant NICU No growth
Disinfectant SICU No growth
Disinfectant MICU No growth
Disinfectant OT (NEURO OT) No growth
Disinfectant OT (OPTHAL OT) No growth
Disinfectant OT (ORTHO OT) No growth
Disinfectant OT (SURGERY OT) No growth
TOTAL 25 Growth in 9 samples
P. aeruginosa: Pseudomonas aeruginosa, A. baumannii: Acinetobacter baumannii, 
MSSA: Methicillin‑susceptible Staphylococcus aureus, MRSA: Methicillin‑resistant 
Staphylococcus aureusHere, imipenem revealed a very good sensitivity rate, 90%, followed by norfloxacin and nitrofurantoin, individually comprises 80%, and next to it was nalidixic acid 70%.
DISCUSSION
Acinetobacter is ubiquitous in nature. However, recently, they have emerged as primary opportunistic pathogens in hospitalized patients as well as immunocompromised patients and responsible for causing variant infections.[12] They are very hard to desiccate, difficult to eradicate and have numerous intrinsic and acquired mechanisms of drug resistance, thus they possess a great threat to the clinician as well as to microbiologists. They can stay alive 
within disinfectants and can create problem in health-care facilities spreading by cross-contamination.[13] They are posing a great threat to human race as they are resistant to routinely used antibiotics. The abuse and the unjudicial practice of antibiotics are responsible for the burgeoning resistance of commonly used antibiotics toward 
Acinetobacter. Moreover, the MDR among these organisms makes the treatment of this infection difficult and expensive.[12]A total of 15,169 clinical samples of pus, wound swab, different body fluid, blood, sputum, and urine were carried out. Of these total sample processed, 5096 (33.59%) were culture positive. A total of 505 (15.9%) NFGNB were obtained from the culture-positive samples. Among these 505 NFGNB, the leading number of isolates was different species of Pseudomonas (189 isolates), followed by 170 isolates of different species of Acinetobacter. All these isolates of Acinetobacter are potential to cause nosocomial infection, ventilator-associated pneumonia (VAP), SSI, bacteremia, respiratory tract infection, and UTI in catheterized patients.We also observed that the infection was common in the patients of the age group of 51–60 years followed by 41–50 years’ age group. In a study by Mindolli et al. isolates Acinetobacter were in the age group of >45 years possibly due to weakened immune system and associated chronic diseases in these age groups.[4,8]There is burgeoning incidence of Acinetobacter species causing serious nosocomial infection worldwide, among which the most prevalent is A. baumannii. In 2011, Sinha et al. studied 9756 samples from which they received 140 different species of 
Acinetobacter among which A. baumannii was the predominant species (92.14%) one.[14] In this present study also, we have isolated different species of Acinetobacter amidst which quite a considerable number of isolates are A. baumannii. The majority of A. baumannii were isolated from pus or wound discharge swab accounting for 36 (37.5%), followed by 29 (30.21%) isolates from different type of body fluids. A. baumannii is the most prevalent human pathogen among all Acinetobacter species and creates a challenge to health-care personnel in terms of treatment and infection control.[15]Nosocomial infections caused by other named Acinetobacter species are burgeoning recently. Similarly, in this study, apart from A. baumannii, other isolates of this genre were A. lwoffii 35 (20.58%), ABC 18 (10.58%), A. radioresistance 8 (4.71%), 
A. calcoaceticus 7 (4.11%), A. haemolyticus 5 (2.94%), and only one isolate of A. ursingii (0.58%) was yield from the drain tip of a patient admitted in male surgery word.
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The highest number of isolates of A. lwoffii was yield from pus and as well as from body fluids, each accounting for 13 isolates. Whereas, only eight isolates of ABC were isolated from body fluid. Six isolates of A. radioresistance were obtained from body fluid, three isolates of A. calcoaceticus yield from pus, three isolates of A. haemolyticus revealed from body fluid, and only one isolate of A. ursingii obtained from the drain fluid of cholecystectomy patients.In this study, majority of Acinetobacter species, including 
A. baumannii, yield from SSI or from the specimen of operated site, accounting for 61 (35.88%) isolates, followed by 36 (21.17%) isolates from the respiratory samples. VAP is the another frequent clinical manifestation of hospital-acquired Acinetobacter infection. However, sometimes, it is difficult to distinguish upper respiratory tract colonization from true infection.[16] We have also observed that the sepsis due to Acinetobacter species is another common finding. Almost 35 (20.58%) isolates were yield from blood samples. To rule out the colonization, two sets of blood samples were collected from each patient.Many studies have analyzed the risk factors for colonization and infection with Acinetobacter. Major surgeries, trauma, SSI, prolonged and previous hospitalization, prolonged hospital stay (more than 72 h), mechanical ventilation, indwelling foreign devices, invasive procedures, and previous antimicrobial therapy all have identified as risk factors predisposing to acquisition of infection with Acinetobacter.[16] In this study, 24.56% isolates were obtained from the patients who had a prolonged hospital stay and in 18% with DM as predisposing factor. Around 21.05% isolates were obtained from the patients, who were on mechanical ventilators, whereas 8% isolates were yield from the patients who had indwelling catheters or orthopedic implants in situ.
ABC and Heterogeneous Group of BacteriaThe genus Acinetobacter comprises a complex and heterogeneous group of bacteria. However, A. baumannii as well as its close relatives belonging to genomic species 3 (Acinetobacter pittii) and 13TU (Acinetobacter nosocomialis), are important nosocomial pathogens, often associated with epidemic outbreaks of infection, that are only rarely found outside of a clinical setting. In 2011, the genus Acinetobacter includes 23 species for which a formal name has been assigned and 11 other recognized additional genomic species without a name, although names have recently been proposed but are not yet formally assigned for genomic species 3 and 13TU. A. baumannii, A. calcoaceticus, genomic species 3 (Acinetobacter pittii), and genomic species 13TU (Acinetobacter 
nosocomialis) are closely related according to DNA-DNA hybridization studies, and can hardly be distinguished according to phenotypic or chemotaxonomic criteria. For convenience, many laboratories often group these genomic species together in the so-called, “A. calcoaceticus-A. baumannii (Acb) complex.’’[16]I n  o u r  l a b o r a t o r y,  w e  w e r e  a b l e  t o  y i e l d  f o u r ‘‘A. calcoaceticus-A. baumannii (Acb) complex,’’ comprising 
A. baumannii, A. calcoaceticus, genomic species 3 (A. pittii), and genomic species 13TU (A. nosocomialis) with the help of VITEK-2 system. One was isolated from the drain tip of a cholecystectomy patient, who was admitted in ICU for a long tenure, the case was an intraoperative sample. The another was again a drain tip and one was isolated from the blood of a patient admitted in ICU with diagnosis of septicemia for a long time. The remarkable thing 
about all these four isolates is that these isolates obtained from the typical cases of HAI.The isolates of A. baumannii obtained from pus or wound swab, body fluid, blood, and sputum revealed 60% were sensitive to imipenem followed by 52.2% susceptibility to chloramphenicol and 48.9% to gentamicin, next to it was amikacin and norfloxacin each comprises 47.8%, in contrast to this study, another study by Rit et al. revealed low susceptibility to chloramphenicol (28%) and gentamicin (24%).[17] In our study, CAZ shows a bit low sensitivity pattern, accounting for 37.8 %. Similarly, a study by Rit et al. reported 28% sensitivity to CAZ.[17]Antibiotic susceptibility pattern of Acinetobacter species, other than A. baumannii, yield from pus, body fluid, blood, and sputum reveal a good sensitivity to imipenem (70%), chloramphenicol (62.85%), followed by amikacin (58.57%), next to it was 54.28% sensitivity to gentamicin. This study revealed a moderate susceptibility to cotrimoxazole (47.14%), and cefotaxime shows 44.28% sensitivity.Antibiotic susceptibility pattern of Acinetobacter species of urinary isolates reveals 90% sensitivity rate to imipenem followed by norfloxacin and nitrofurantoin, individually comprises 80%, and next to it was nalidixic acid 70% and cotrimoxazole 60%. Amikacin, cefotaxime, and gentamicin each of them show 50%. CAZ and ampicillin show 40% and 10%, respectively.
Acinetobacter poses a threat to health-care community as they represent the problem of MDR to the commonly used antibiotics. 
There are limited data on β-lactamase producing Acinetobacter species from India. In our study, 57.38% of Acinetobacter species were ESBL producer and 22.5% were MBL producers by the CDDT. Kansal et al. and Kumar et al. found the 75% of ESBL producing and 21% of MBL producing isolates in their study, respectively.[7,18,19] Due to different antimicrobial susceptibility pattern in different hospitals, these surveillance studies are valuable in deciding the most adequate therapy for Acinetobacter infections. In our study, 61 (35.6%) isolates were MDR strains. 
Acinetobacter appears to have a propensity to develop antibiotic resistance extremely rapidly, perhaps as a consequence of its long-term evolutionary exposure to antibiotic-producing organisms in soil environment.[7,20] The emergence of antibiotic-resistant strains in ICUs is because of higher use of antimicrobial agents per patient and per surface area.[7,21]As rates of infection have increased, so the incidence of infection with MDR isolates of Acinetobacter species is also increasing. Providing effective treatment for infections caused by MDR 
Acinetobacter is a challenge. MDR strains typically require therapy with colistin, an older and relatively toxic polymyxin antimicrobial, and aminoglycosides or with the newer antimicrobial agent like tigecycline.[21,22] In our study, the Acinetobacter isolated which is pan resistant, i.e., resistant to all the antibiotics we have used; colistin was the last resort for drug of choice for these isolates.
CONCLUSIONA large number of Acinetobacter are isolated as primary pathogen from different clinical specimens of the patients, admitted in different wards and ICUs in this institution. The remarkable thing about all these isolates is that these isolates obtained from 
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the typical cases of HAI. Most of the patients had high-risk factors such as prolonged hospitalization, immunocompromised due to chemotherapy, indwelling catheters and orthopedics implants in 
situ or other catheterization (urinary or intravenous), diabetes mellitus, and burns. These organisms have possibly come from inanimate objects such as ventilator, humidifier, washbasin, and from diluted disinfections.Most effective antibiotics are imipenem, amikacin, gentamicin, ciprofloxacin, cefotaxime, and cotrimoxazole. Most of the strains of Acinetobacter were resistant to penicillin, whereas carbapenem groups of drugs showed good sensitive.A quite high number of isolated Acinetobacter species are MDR strains and most of them are resistant to commonly used antibiotics. This is an alarming indication that Acinetobacter species should need to be taken more seriously as primary pathogen and should not be discarded as mere contaminant or non-pathogen. Hence, proper isolation and identification of these organisms can enlighten their prevalence rate and the role of pathogenicity among hospitalized patients.There is a widespread variability of antibiotic profile in common hospital for these pathogens. The antibiotic susceptibility can change from hospital to hospital set up, and there may be a gross geographical variation. Hence, it is imperative that every hospital should monitor a proper antibiogram profile for these isolated from time to time to serve as a basic empirical therapy to prevent the development of MDR cases.Treating these pathogens should be based on the laboratory data after identifying the proper causative agents and antibiotic susceptibility result. Minimized the use and abuse of antimicrobial agents, proper surveillance of antibiotic panel, strict infection control measures, and even simple yet proper handwashing method and using disinfection of inanimate objects, can prevent the emergence Acinetobacter and can reduce the rate of MDR strains.
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